237 related articles for article (PubMed ID: 24366192)
41. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
42. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
[TBL] [Abstract][Full Text] [Related]
43. Acute myeloid leukemia following a myeloproliferative neoplasm: clinical characteristics, genetic features and effects of therapy.
Heaney ML; Soriano G
Curr Hematol Malig Rep; 2013 Jun; 8(2):116-22. PubMed ID: 23572311
[TBL] [Abstract][Full Text] [Related]
44. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
45. Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms.
Beer PA; Ortmann CA; Stegelmann F; Guglielmelli P; Reilly JT; Larsen TS; Hasselbalch HC; Vannucchi AM; Möller P; Döhner K; Green AR
Haematologica; 2010 Dec; 95(12):2153-6. PubMed ID: 20823136
[TBL] [Abstract][Full Text] [Related]
46. Clinical and molecular genetic characterization of myelofibrosis.
Hobbs GS; Rampal RK
Curr Opin Hematol; 2015 Mar; 22(2):177-83. PubMed ID: 25635755
[TBL] [Abstract][Full Text] [Related]
47. Thrombosis in myeloproliferative neoplasms.
Falanga A; Marchetti M
Semin Thromb Hemost; 2014 Apr; 40(3):348-58. PubMed ID: 24610470
[TBL] [Abstract][Full Text] [Related]
48. Mutations in the miR-142 gene are not common in myeloproliferative neoplasms.
Galka-Marciniak P; Kanduła Z; Tire A; Wegorek W; Gwozdz-Bak K; Handschuh L; Giefing M; Lewandowski K; Kozlowski P
Sci Rep; 2022 Jun; 12(1):10924. PubMed ID: 35764886
[TBL] [Abstract][Full Text] [Related]
49. The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation.
Reikvam H; Hatfield KJ; Fredly H; Nepstad I; Mosevoll KA; Bruserud Ø
Eur Cytokine Netw; 2012; 23(4):140-53. PubMed ID: 23328436
[TBL] [Abstract][Full Text] [Related]
50. [Metamorphosis of chronic myeloproliferative diseases].
Butoianu E; Nicoară S; Coliţă A; Ursea C; Berceanu S
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1983; 35(3):223-32. PubMed ID: 6140716
[No Abstract] [Full Text] [Related]
51. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms.
Stein BL; Crispino JD; Moliterno AR
Curr Opin Oncol; 2011 Nov; 23(6):609-16. PubMed ID: 21993415
[TBL] [Abstract][Full Text] [Related]
52. How to manage thrombosis in myeloproliferative neoplasms.
Barbui T
Curr Opin Oncol; 2011 Nov; 23(6):654-8. PubMed ID: 21986846
[TBL] [Abstract][Full Text] [Related]
53. [Successful treatment with interferon-alpha in a case of acute myeloid leukemia with del (20q) following polycythemia vera].
Sumi M; Tauchi T; Takaku T; Ohyashiki JH; Ohyashiki K
Rinsho Ketsueki; 2005 Nov; 46(11):1208-12. PubMed ID: 16440805
[TBL] [Abstract][Full Text] [Related]
54. Transplant decision-making strategies in the myeloproliferative disorders.
Fruchtman SM
Semin Hematol; 2003 Jan; 40(1 Suppl 1):30-3. PubMed ID: 12682880
[TBL] [Abstract][Full Text] [Related]
55. Practical management of classical myeloproliferative disorder patients: a clinician's guide.
Mesa RA
Future Oncol; 2006 Aug; 2(4):515-24. PubMed ID: 16922618
[TBL] [Abstract][Full Text] [Related]
56. A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia.
Goyal H; Chachoua I; Pecquet C; Vainchenker W; Constantinescu SN
Blood Rev; 2020 Jul; 42():100712. PubMed ID: 32660739
[TBL] [Abstract][Full Text] [Related]
57. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
Mesa RA; Jamieson C; Bhatia R; Deininger MW; Fletcher CD; Gerds AT; Gojo I; Gotlib J; Gundabolu K; Hobbs G; McMahon B; Mohan SR; Oh S; Padron E; Papadantonakis N; Pancari P; Podoltsev N; Rampal R; Ranheim E; Reddy V; Rein LAM; Scott B; Snyder DS; Stein BL; Talpaz M; Verstovsek S; Wadleigh M; Wang ES; Bergman MA; Gregory KM; Sundar H
J Natl Compr Canc Netw; 2017 Oct; 15(10):1193-1207. PubMed ID: 28982745
[TBL] [Abstract][Full Text] [Related]
58. Myeloproliferative neoplasia: a review of clinical criteria and treatment.
Koopmans SM; van Marion AM; Schouten HC
Neth J Med; 2012 May; 70(4):159-67. PubMed ID: 22641623
[TBL] [Abstract][Full Text] [Related]
59. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
[TBL] [Abstract][Full Text] [Related]
60. Advances in understanding and management of polycythemia vera.
Vannucchi AM; Guglielmelli P
Curr Opin Oncol; 2010 Nov; 22(6):636-41. PubMed ID: 20805747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
